VA Expands Access to Amyloidosis Treatment

May 08, 2025

A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils

Read more

May 05, 2025

Facilitating an Early Diagnosis in ATTR-CM

Read more

Apr 28, 2025

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Read more

Apr 05, 2025

Confirming the Benefit of SGLT2 Inhibitors in People With ATTR Amyloidosis, with Justin Riley Lam, MD

Read more

Apr 05, 2025

Senescence Accelerates the Occurrence of Dual Amyloidosis: Alzheimer's Disease and Wild-Type Transthyretin Amyloidosis

Read more

Apr 02, 2025

Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity

Read more

Apr 01, 2025

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

Read more

Mar 20, 2025

RNAi Therapeutics Market Growth 2024-2025

Read more

Mar 17, 2025

Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space

Read more

Mar 13, 2025

Allele-specific electrical genotyping for diagnosis of transthyretin amyloidosis

Read more

Subscribe to